The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

Provided herein are a biarylsulfonamide, e.g., a compound of Formula (IA), and a pharmaceutical composition thereof. Also provided herein is a method of treating a fibrotic lung disease with a biarylsulfonamide, alone or in combination with an antifibrotic agent. Additionally, provided herein is a method of slowing the rate of decline in pulmonary function in a subject having a fibrotic lung disease with a biarylsulfonamide, alone or in combination with an antifibrotic agent.

##STR00001##

Provided herein are a biarylsulfonamide, e.g., a compound of Formula (IA), and a pharmaceutical composition thereof. Also provided herein is a method of treating a fibrotic lung disease with a biarylsulfonamide, alone or in combination with an antifibrotic agent. Additionally, provided herein is a method of slowing the rate of decline in pulmonary function in a subject having a fibrotic lung disease with a biarylsulfonamide, alone or in combination with an antifibrotic agent.

##STR00001##

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.